AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 31075462
Drug: Anticoagulation therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anticoagulation therapy (without filter placement)
Trial: 26493425
Drug: Acceptance and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acceptance and Commitment Therapy (10 sessions of 90 minutes)
Trial: 23872222
Drug: Fludarabine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 120 mg/m(2) + Melphalan 100 mg/m(2) (FM100)
Trial: 23872222
Drug: Fludarabine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 120 mg/m(2) + Melphalan 140 mg/m(2) (FM140)
Trial: 16579891
Drug: Sublingual misoprostol,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual misoprostol, 600 g
Trial: 16278618
Drug: E(2) 1
RxNorm normalized name: vitamin E 1 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2) 1 mg/NETA 0.5 mg
Trial: 16278618
Drug: E(2) 1
RxNorm normalized name: vitamin E 1 UNT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: E(2) 1 mg/NETA 0.25 mg
Trial: 8196848
Drug: SCMC‐Lys (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SCMC‐Lys (750 mg/die in a linctus formula for 10 days and 2.7 g in a granular formula once a day for a maximum of 15 days)
Trial: 3148381
Drug: Intensive subcutaneous
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive subcutaneous insulin injections
Trial: 20205606
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (SQT)
Trial: 8707437
Drug: Indium‐111 monoclonal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indium‐111 monoclonal antimyosin antibody imaging
Trial: 2387950
Drug: Calcium (1.558
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium (1.558 g) and vitamin D (45 micrograms or 1,800 IU) administered daily for 11 weeks
Trial: 7325347
Drug: 0.3 mg
RxNorm normalized name: biotin 0.3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.3 mg Buprenorphine (Temgesic)
Trial: 7325347
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg Nicomorphine (Vilan)
Trial: 30771856
Drug: B-vitamin supplementation
RxNorm normalized name: VITAMIN B
DrugBank: Inositol (DB13178)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: B-vitamin supplementation (folic acid [5 mg], B12 [0.4 mg], B6 [50 mg])
Trial: 23890764
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of naltrexone/disulfiram
Trial: 19408641
Drug: Bupivacaine 0.25%
RxNorm normalized name: BUPIVACAINE 0.25%/NS INJ 400ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 0.25% with tramadol 100 mg
Trial: 16009749
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of telephone directories and religious sources
Trial: 11914248
Drug: High-dose intracoronary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intracoronary beta-radiation
Trial: 9818750
Drug: Cefpirome (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefpirome (2 g bd iv)
Trial: 9818750
Drug: Ceftazidime (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftazidime (2 g tds iv)
Trial: 4064532
Drug: Buscopan (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buscopan (20 mg)
Trial: 798660
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Dantrium and Valium
Trial: 26033972
Drug: rhBMP-12/ACS group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rhBMP-12/ACS group (0.015 mg/mL)
Trial: 21455339
Drug: Aethoxysklerol injection
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aethoxysklerol injection
Trial: 21455339
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hemoclip hemostasis with aethoxysklerol injection
Trial: 17239277
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of differential expression, chromosomal alteration, and pathways signature analysis
Trial: 11774270
Drug: Screening for
RxNorm normalized name: SUN PROTECTANTS/SCREENS,TOPICAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Screening for prostate cancer using serum prostate-specific antigen (PSA) and digital rectal examination (DRE) as an ancillary test.
Trial: 9419169
Drug: Valaciclovir, 8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valaciclovir, 8 g/day
Trial: 9419169
Drug: Acyclovir, 3.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acyclovir, 3.2 or 0.8 g/day
Trial: 2539346
Drug: Ro 03-8799
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 03-8799 (0.75 g/m2) and SR 2508 (2 g/m2) administered three times per week for 15 doses
Trial: 2539346
Drug: Ro 03-8799
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 03-8799 (0.75 g/m2) and SR 2508 (2 g/m2) administered three times per week for 12 doses
Trial: 2539346
Drug: Ro 03-8799
RxNorm normalized name: RO-5045337
DrugBank: RO-5045337 (DB14793)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ro 03-8799 and SR 2508 combination
Trial: 31223399
Drug: Intramuscular injection
RxNorm normalized name: rabies, intramuscular injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular injection of ketoprofen 100mg
Trial: 31223399
Drug: Lidocaine and
RxNorm normalized name: Lidocaine and Tetracaine
DrugBank: Tetracaine (DB09085)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine and prilocaine topical cream
Trial: 27558280
Drug: Azilsartan medoxomil
RxNorm normalized name: Azilsartan Medoxomil
DrugBank: Azilsartan medoxomil (DB08822)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Azilsartan medoxomil (AZL-M) (all doses)
Trial: 27558280
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil (OLM) 20 mg
Trial: 23250194
Drug: Concurrent physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concurrent physical activity (PA)
Trial: 19293130
Drug: Immediate switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate switch to 4.6 mg/24 h rivastigmine transdermal patch
Trial: 19293130
Drug: Delayed switch
RxNorm normalized name: Witch Hazel
DrugBank: Witch hazel (DB11111)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed switch to 4.6 mg/24 h rivastigmine transdermal patch
Trial: 20395684
Drug: Donepezil 5-10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5-10 mg/day
Trial: 17501956
Drug: TCHM (Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCHM (Chinese herbal medicine concoction), 3 capsules twice daily for 12 weeks
Trial: 17501956
Drug: Placebo, 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 3 capsules twice daily for 12 weeks
Trial: 17501956
Drug: TCHM (Chinese
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TCHM (Chinese herbal medicine concoction)
Trial: 15494274
Drug: Early hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Early hydrocortisone treatment (n = 9)
Trial: 15494274
Drug: Early hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Early hydrocortisone treatment
Trial: 11847472
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone treatment (0.15 IU/kg/day)
Trial: 2889554
Drug: Bopindolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bopindolol (2 mg, administered orally)
Trial: 2889554
Drug: Bopindolol (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bopindolol (2 to 4 mg, administered orally)
Trial: 28857785
Drug: i‐gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i‐gel
Trial: 27160490
Drug: Intrathecal magnesium
RxNorm normalized name: beractant
DrugBank: Beractant (DB06761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intrathecal magnesium sulphate (375 μg/rat) prior to intrathecal morphine (10 μg/rat)
Trial: 27160490
Drug: Intrathecal mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal mixture of 1 mg of morphine with 3 mL hyperbaric 0.5% bupivacaine
Trial: 27160490
Drug: Intrathecal mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal mixture of morphine with bupivacaine and 50 mg of magnesium sulphate
Trial: 27160490
Drug: Intrathecal mixture
RxNorm normalized name: brown mixture
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal mixture of morphine bupivacaine plus IV 20 mg/kg of magnesium sulphate as a loading dose over 15 min, followed by infusion at a rate of 10 mg/kg/h
Trial: 24895810
Drug: Plasma exchange
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma exchange (PE) plus standard medical treatment
Trial: 22266041
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (E1594 and E4599)
Trial: 22266041
Drug: Bevacizumab treatment
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab treatment (E4599)
Trial: 18408919
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg tandospirone
Trial: 15900355
Drug: Atenolol 50
RxNorm normalized name: atenolol 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atenolol 50 mg (non-chewing controls)
Trial: 10875051
Drug: Drug treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug treatment (mainly antidepressants)
Trial: 10875051
Drug: Cognitive‐behaviour therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive‐behaviour therapy
Trial: 10875051
Drug: Self‐help therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Self‐help therapy
Trial: 26869460
Drug: One daily
RxNorm normalized name: One Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily physical exercise unit at school for 4 years
Trial: 26869460
Drug: Conventional school
RxNorm normalized name: schorl tourmaline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional school sports twice a week
Trial: 26869460
Drug: One daily
RxNorm normalized name: One Daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One daily physical exercise unit at school
Trial: 21851602
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea extract containing 150 mg EGCG two times daily
Trial: 16367882
Drug: Rosiglitazone (RSG)
DrugBank: Rosiglitazone (DB00412)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rosiglitazone (RSG) 4 mg once daily plus glipizide 10 mg twice daily
Trial: 16367882
Drug: Sulphonylurea (SU)
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylurea (SU) dose escalation plus placebo
Trial: 16367882
Drug: Sulphonylurea (SU)
RxNorm normalized name: Sus scrofa skin
DrugBank: Sus scrofa skin (DB10606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphonylurea (SU) dose escalation
Trial: 12635001
Drug: Concentrated ambient
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concentrated ambient particulates (CAP) at an average concentration of 174 micro g/m(3) for 2 hours with alternating rest-exercise periods.
Trial: 1360991
Drug: Phenindamine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenindamine (25 mg)
Trial: 6581756
Drug: Bright artificial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bright artificial light therapy
Trial: 23178916
Drug: Adalimumab plus
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab plus adjunctive topical therapy (calcipotriol/betamethasone dipropionate)
Trial: 23178916
Drug: Adalimumab plus
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adalimumab plus matching topical vehicle (monotherapy)
Trial: 15578006
Drug: olanzapine (10‐20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: olanzapine (10‐20 mg/day)
Trial: 15578006
Drug: amisulpride (400‐800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: amisulpride (400‐800 mg/day)
Trial: 6340453
Drug: Verapamil (0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (0.2 mg/kg over 10 minutes)
Trial: 27548249
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy (6 mg·kg·day) plus placebo
Trial: 27548249
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy (6 mg·kg·day) plus vitamin E (18 mg/day)
Trial: 27548249
Drug: Iron therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iron therapy (6 mg·kg·day) plus placebo and vitamin E
Trial: 15876664
Drug: Compound probability
RxNorm normalized name: BENZOIN COMPOUND
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound probability density function parameters including the speckle factor and K distribution parameter
Trial: 7828131
Drug: VAD plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAD plus oral verapamil (VAD/v)
Trial: 1964218
Drug: Local step-by-step
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Local step-by-step intrapulmonary administration of glucocorticosteroids (GCS)
Trial: 24411286
Drug: Ultrasound-guided para-aneurysmal
RxNorm normalized name: para-cresol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided para-aneurysmal saline injection (PASI)
Trial: 15220031
Drug: donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil (5 mg/day)
Trial: 15220031
Drug: donepezil (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: donepezil (5 or 10 mg/day)
Trial: 9683718
Drug: iodixanol (Visipaque;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iodixanol (Visipaque; 320 mg I/ml)
Trial: 9683718
Drug: iohexol (Omnipaque;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: iohexol (Omnipaque; 300 mg I/ml)
Trial: 8023589
Drug: Nonsteroidal antiinflammatory
RxNorm normalized name: Arthriten Inflammatory Pain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonsteroidal antiinflammatory drugs (NSAID)
Trial: 3072358
Drug: Ketoprofen 225
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 225 mg
Trial: 26400874
Drug: Morning dosing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morning dosing of antihypertensive medications
Trial: 29211509
Drug: Evening dosing
RxNorm normalized name: Evening Dosing 24 HR Jornay 60 MG Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Evening dosing of antihypertensive medications
Trial: 23422867
Drug: Isoflavone soy
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflavone soy protein (ISP) supplementation, 154 mg daily for 3 years
Trial: 19371188
Drug: Conventional-dose statin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional-dose statin therapy
Trial: 14503436
Drug: Conventional therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional therapy program for mobility
Trial: 10797496
Drug: Immediate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate treatment for localized prostate cancer
Trial: 10797496
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of localized disease
Trial: 10797496
Drug: Screening procedures
RxNorm normalized name: hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Screening procedures and treatments for localized prostate cancer
Trial: 1443705
Drug: M-K-A (midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-K-A (midazolam 0.5 mg/kg, ketamine 3 mg/kg, atropine 0.02 mg/kg)
Trial: 1443705
Drug: M-A (midazolam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: M-A (midazolam 0.5 mg/kg, atropine 0.02 mg/kg)
Trial: 1443705
Drug: K-A (ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: K-A (ketamine 3 mg/kg, atropine 0.02 mg/kg)
Trial: 1443705
Drug: A (atropine
RxNorm normalized name: B-Donna (atropine sulfate 0.0194 MG / hyoscyamine sulfate 0.1037 MG / phenobarbital 16.2 MG / scopolamine hydrobromide 0.0065 MG) Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A (atropine 0.02 mg/kg)
Trial: 29949323
Drug: Mild hormonally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mild hormonally stimulated cycle by low dose Clomiphene Citrate (n=30)
Trial: 12435668
Drug: Intravenous (i.v.)
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous (i.v.) infusion of 400 mg ciprofloxacin over 60 min
Trial: 12435668
Drug: Oral (p.o.)
RxNorm normalized name: Oral Film
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral (p.o.) dose of 500 mg ciprofloxacin
Trial: 12435668
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro model simulating in vivo pharmacokinetics
Trial: 10357120
Drug: Deflazacort oral
RxNorm normalized name: deflazacort Oral Tablet
DrugBank: Deflazacort (DB11921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deflazacort oral drops
Trial: 10357120
Drug: Deflazacort oral
RxNorm normalized name: deflazacort Oral Tablet
DrugBank: Deflazacort (DB11921)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Deflazacort oral tablets
Trial: 6787746
Drug: High voltage
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High voltage therapy of the retrobulbar region
Trial: 30683945
Drug: IIGI+saline (154
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IIGI+saline (154 mmol/l NaCl; placebo)
Trial: 24073975
Drug: Sildenafil 100
RxNorm normalized name: sildenafil 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil 100 mg and 50 mg
Trial: 19169684
Drug: Fotemustine (100-75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fotemustine (100-75 mg/m2) administered every three weeks followed by fotemustine (100 mg/m2) every three weeks after a 5-week rest for up to 1 year.
Trial: 19169684
Drug: Induction phase
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Induction phase of fotemustine treatment.
Trial: 19169684
Drug: Maintenance phase
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance phase of fotemustine treatment.
Trial: 16755856
Drug: Vilarinum in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vilarinum in addition to conventional treatment (beta‐adrenoblockers, antiaggregants, and statins)
Trial: 9823645
Drug: Artroflow device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Artroflow device used three times a day for 30 minutes in addition to Enoxaparin 1 x 40 mg subcutaneously per day.
Trial: 9823645
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group receiving only Enoxaparin 1 x 40 mg subcutaneously per day.
Trial: 2560621
Drug: Surgery plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery plus adjuvant chemotherapy (n = 8)
Trial: 785735
Drug: 30 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/kg matrix isoniazid
Trial: 785735
Drug: Higher doses
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher doses of matrix isoniazid
Trial: 785735
Drug: 30-40 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30-40 mg/kg matrix isoniazid
Trial: 27862308
Drug: Alemtuzumab consolidation
RxNorm normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Alemtuzumab consolidation therapy (10 mg intravenously once weekly for 8 weeks, escalating in 10 mg intervals)
Trial: 25481662
Drug: Palliative concurrent
RxNorm normalized name: Various pain palliation radiopharmaceuticals
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palliative concurrent chemoradiotherapy (CRT) with 4 courses of intravenous carboplatin and oral vinorelbine, plus radiotherapy (42 Gy in 15 fractions)
Trial: 23774931
Drug: Target-controlled infusion
RxNorm normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Target-controlled infusion (TCI) of propofol and remifentanil
Trial: 23774931
Drug: Manual-controlled infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Manual-controlled infusion (MCI) of propofol and remifentanil
Trial: 21627767
Drug: Micro-TENS therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Micro-TENS therapy